Leading the way IN DIAGNOSTICS
INNOVATION THAT DRIVES GROWTH

DRIVING DIAGNOSTIC INNOVATION SINCE 1972

More than 30,000 CUSTOMERS around THE WORLD

1,500 scientists and engineers GLOBALLY

10 manufacturing and 10 R&D sites GLOBALLY

1ST COMPANY to simultaneously launch 6 new testing platforms

1ST

• World’s 1st HIV test
• 1st FDA-approved hepatitis C genotype test
• 1st FDA-approved gene-based companion diagnostics test for breast cancer

ABOUT 4 BILLION TESTS RUN ANNUALLY

in point-of-care diagnostics (U.S.) and in blood screening (Worldwide)

NO. 1 Leader in IN VITRO DIAGNOSTICS with $4.8 BILLION IN SALES

TESTS SCREEN more than 60% of the world’s BLOOD SUPPLY

5 YEARS OF MID-TO-HIGH-SINGLE-DIGIT operational sales growth WITH SAME PROJECTION FOR 2017